Under construction – not a live service
Sign in
Not yet taking people in ChinaPhase 3

Eloralintide Study for Weight, Diabetes and Heart Risk in Adults

Tests eloralintide against placebo in adults with obesity, diabetes and heart risk.

Key facts

Who runs it
Eli Lilly and Company
Where
Beijing, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan, Liaoyou, Luoyang Shi, Nanjing, Shanghai, Shijiazhuang, Tianjin, Wenzhou, Xuzhou, Yibin, and Zigong, ChinaSee the 21 sitesAlso in 20 other countries, 286 sites
Registry title
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
Status
Not yet recruiting
Phase
Phase 3
People taking part
3,000 people, planned
Starts
Dec 2026
Expected to end
Dec 2029
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Eloralintide
  • Placebo
Record updated
3 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 45 to 64 with type 2 diabetes, overweight or obesity, and a higher risk of heart and blood vessel problems.

Age
45 to 64 years
Sex
All sexes can join.
Disease stage
Type 2 diabetes with HbA1c between ≥ 6.5% (48 mmol/mol) and ≤ 9.5% (80 mmol/mol), BMI ≥ 25.0 kg/m2, and an increased risk of cardiovascular events.
Earlier treatment
On stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening. At least one self-reported unsuccessful dietary effort to lose weight.
Biomarker or test result
HbA1c between ≥ 6.5% (48 mmol/mol) and ≤ 9.5% (80 mmol/mol) at screening.

Main reasons for not taking part

  • Type 1 diabetes
  • Prior or planned surgery, endoscopic procedure or device-based therapy for obesity (some exceptions apply)
  • New York Heart Association Functional Classification IV congestive heart failure
  • Within 60 days before screening: heart attack, stroke, hospitalization for heart failure, or artery revascularization
  • Sulfonylurea combined with insulin within 90 days before screening

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Have type 2 diabetes
  • Have a HbA1c value between ≥ 6.5% and ≤ 9.5% at screening
  • Are on stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening
  • Have an increased risk of cardiovascular events
  • Have a BMI ≥ 25.0 kg/m2 at screening
  • Have a stable body weight (<5% body weight change) for 90 days prior to screening
  • Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight

Who cannot take part

  • Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening)
  • Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
  • Have had within 60 days prior to screening:; acute myocardial infarction; stroke; hospitalization for congestive heart failure, or; coronary, peripheral, or carotid artery revascularization procedure
  • Have received treatment combining sulfonylurea and insulin within 90 days prior to screening
  • Have type 1 diabetes
  • Have a history or diagnosis of New York Heart Association Functional Classification IV congestive heart failure

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 45 and 64 years old?

Where in China

Also in 20 other countries, 286 sites

  • Peking University Third HospitalBeijing, ChinaContact: Dan Zhu (principal investigator)No longer taking part
  • Xuanwu Hospital, Capital Medical UniversityBeijing, ChinaContact: Yu Sun (principal investigator)No longer taking part
  • Sichuan Provincial People's HospitalChengdu, ChinaContact: Limin Tian (principal investigator)No longer taking part
  • West China Hospital，Sichuan UniversityChengdu, ChinaContact: Fang Liu (principal investigator)No longer taking part
  • Zhujiang HospitalGuangzhou, ChinaContact: Haibo Long (principal investigator)No longer taking part
  • The Second Affiliated Hospital of Zhejiang University School of Medicine - Jiefanglu CampusHangzhou, ChinaContact: Xiaojie Xie (principal investigator)No longer taking part
  • The First Hospital of Harbin Medical UniversityHarbin, ChinaContact: Yue Li (principal investigator)No longer taking part
  • Jinan Central HospitalJinan, ChinaContact: Nianrong Mi (principal investigator)No longer taking part
  • Panjin Liaoyou Baoshihua HospitalLiaoyou, ChinaContact: Ju Gao (principal investigator)No longer taking part
  • The First Affiliated Hospital of Henan University of Science &TechnologyLuoyang Shi, ChinaContact: Hongwei Jiang (principal investigator)No longer taking part
  • Nanjing First HospitalNanjing, ChinaContact: Qian Li (principal investigator)No longer taking part
  • Zhongda Hospital Southeast UniversityNanjing, ChinaContact: Ling Li (principal investigator)No longer taking part
  • Jiading District Central HospitalShanghai, ChinaContact: Lixia Suo (principal investigator)No longer taking part
  • Shanghai Putuo District Center HospitalShanghai, ChinaContact: Zongjun Liu (principal investigator)No longer taking part
  • Hebei General HospitalShijiazhuang, ChinaContact: Luping Ren (principal investigator)No longer taking part
  • The Third Hospital of Hebei Medical UniversityShijiazhuang, ChinaContact: Yanqing Chi (principal investigator)No longer taking part
  • Tianjin Medical University General HospitalTianjin, ChinaContact: Ming Liu (principal investigator)No longer taking part
  • The 2nd Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical UniversityWenzhou, ChinaContact: Chaoming Wu (principal investigator)No longer taking part
  • The Affiliated Hospital of Xuzhou Medical CollegeXuzhou, ChinaContact: Hong Zhu (principal investigator)No longer taking part
  • The Second People's Hospital of YibinYibin, ChinaContact: Chenli Zhang (principal investigator)No longer taking part
  • Zigong First People's HospitalZigong, ChinaContact: Jian Li (principal investigator)No longer taking part

About the trial

What the trial wants to find out

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.

The 2 groups in the trial

  • EloralintideTreatment being tested

    Participants will receive eloralintide subcutaneously (SC)

  • PlaceboPlacebo, for comparison

    Participants will receive placebo SC

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk
Plain-language title
Eloralintide Study for Weight, Diabetes and Heart Risk in AdultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07900633, who can take part
Record updated
3 November 2026